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Abstract 
The MECOM locus in chromosome band 3q26.2 
gives rise to two major mRNA and protein species, 
EVI1 and MDS1/EVI1, of which the former has 
been characterized far more extensively.  
EVI1 has been implicated in the maintenance and 
expansion of normal hematopoietic stem cells. In 
addition, it plays a role as an oncogene in myeloid 
leukemia and in certain solid tumors, its 
overexpression being associated with a dismal 
prognosis in several of these malignancies.  
EVI1 exerts its biological effects mainly by 
regulating gene transcription, and does so by acting 
as a sequence specific transcription factor, by 
modulating the activity of other sequence specific 
transcription factors, and by regulating promoter 
CpG island methylation. 
Keywords 
Transcription regulation, myeloid leukemia, therapy 
resistance, hematopoietic stem cells 
Identity 
Other names: EVI1, PRDM3 




The human EVI1 gene spans approximately 65 kb of 
genomic DNA. 14 of its 16 exons are coding (Fig. 
1A).  
Transcription can initiate from alternative exons 1a, 
1b, 1c, 1d, or 3L (Fig. 1B), and several alternative 
splice variants of the EVI1 mRNA have been 
described (Delta324, -Rp9, Delta105; Fig. 1A). 
The human MDS1 gene consists of 4 exons spread 
over a genomic region of more than 500 kb. 
MDS1 exon 4 is located less than 2 kb upstream of 
EVI1 exon1a. MDS1 can also be expressed on its 
own.  
The MDS1/EVI1 mRNA presumably results from 
splicing of the second exon of MDS1 to the second 
exon of EVI1 (Fig. 1B). 
Transcription 
Telomere to centromere. 
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Genomic locus of the human EVI1 gene, and EVI1 and MDS1/EVI1 mRNA variants. Asterisk, translation initiation codon in EVI1 
exon 3; diamond, translation stop codon in EVI1 exon 16. (This figure was reprinted from Gene 396, R. Wieser, 'The oncogene 
and developmental regulator EVI1: Expression, biochemical properties, and biological functions', pages 346-357, Copyright 





Exon 3 of the human EVI1 gene contains two closely 
spaced ATG codons, either of which may serve as 
the translation initiation site. Depending on which 
ATG is used, proteins of 1051 or 1041 amino acids 
will be formed. EVI1 contains two domains of seven 
and three zinc finger motifs, respectively, a 
repression domain between the two sets of zinc 
fingers, and an acidic domain at its C-terminus. It is 
a 145 kDa protein that is capable of binding to DNA 
in a sequence specific manner, and that interacts with 
transcriptional coactivators and corepressors as well 
as other sequence specific transcription factors. 
DNA binding and transcriptional regulation by EVI1 
are influenced by posttranslational modifications 
like phosphorylation, acetylation, and sumoylation 
(Chakraborty et al, 2001; Shimahara et al, 2010; 
Bard-Chapeau et al, 2013; Singh et al, 2013; White 
et al, 2013). 
Predicted translation of MDS1-EVI1 adds 188 
amino acids to the N-terminus of EVI1. 63 of these 
additional amino acids are encoded by exon 2 and 
beginning of exon 3 of EVI1, and the remaining 125 
from the MDS1 gene. MDS1-EVI1 contains a PR 
domain, which is about 40% homologous to the N-
terminus of the retinoblastoma-binding protein, RIZ, 
and the PRDI-BF1 transcription factor. Some 
biological functions of MDS1/EVI1 were reported to 
be different from, or even antagonistic to, those of 
EVI1, while in other cases, EVI1 and  
MDS1/EVI1 acted in a similar manner. MDS1/EVI1 
(PRDM3) has H3K9me1 methyltransferase activity 
and a role in maintaining heterochromatin integrity 
(Pinheiro et al, 2012). 
Expression 
Among human tissues/organs, the EVI1 mRNA is 
expressed abundantly in kidney, lung, pancreas, 
stomach, ovaries, uterus, and prostate, to a lesser 
extent in the small intestine, colon, thymus, spleen, 
heart, brain, testis, and placenta, and at very low 
levels in skeletal muscle and bone marrow. The 
pattern of expression of MDS1-EVI1 is very similar 
to that of EVI1. 
In the adult mouse, the Evi1 mRNA is expressed, at 
varying levels, in the kidney, lung, stomach, ovary, 
uterus, intestine, thymus, spleen, heart, brain, and 
liver. In the mouse embryo, Evi1 mRNA levels are 
high in the urinary system and Mullerian ducts, the 
lung, the heart, and the emerging limb buds. 
Similar Evi1 expression patterns were also observed 
in Xenopus, chicken, and zebrafish. 
In human and murine hematopoiesis, EVI1 mRNA 
levels are high in the most immature cell populations 
and decline in the course of differentiation (Kataoka 
et al, 2011; Bindels et al, 2012; Steinleitner et al, 
2012). 
EVI1 expression is regulated by RUNX1 and ELK1, 
by retinoic acid via RAR/RXR, and by certain MLL 
fusion proteins (Bingemann et al, 2009; Arai et al, 
2011; Maicas et al, 2013). 
Localisation 
Nuclear; in part in speckles. 
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EVI1 and MDS1/EVI1 protein domains. Black boxes, zinc finger motifs; RD, repression domain; ac, acidic region; PR, PR 
domain. This figure was reprinted in modified form from Gene 396, R. Wieser, 'The oncogene and developmental regulator EVI1: 
Expression, biochemical properties, and biological functions', pages 346-357, Copyright Elsevier (2007), with permission from 
Elsevier. Gene homepage: http://www.sciencedirect.com/science/journal/03781119. 
 
Function 
Because of the spatially and temporally restricted 
expression of MECOM, it has been suggested that 
this gene plays important roles in development and 
could be involved in organogenesis, cell migration, 
cell growth, and differentiation. 
In the mouse, homozygous disruption of the 6th exon 
of the Evi1 gene led to embryonic lethality, with 
widespread hypocellularity, reduced body size, 
small or absent limb buds, a pale yolk sac and 
placenta, abnormal development of the nervous 
system and the heart, and massive haemorrhaging. 
(Hoyt et al, 1997). Functions of Evi1 and/or 
Mds1/Evi1 in heart development, spine formation, 
and, particularly, maintenance and expansion of 
hematopoietic stem cells (HSCs) have been deduced 
from, or confirmed through, the phenotypes of 
additional MECOM knockout models (Goyama et 
al, 2008; Kataoka et al, 2011; Zhang et al, 2011; 
Bard-Chapeau et al, 2014; Juneja et al, 2014). A role 
of Evi1 in HSCs was also corroborated through 
overexpression and gene marking experiments 
(Buonamici et al, 2004; Laricchia-Robbio et al, 
2008; Dickstein et al, 2010; Kataoka et al, 2011). 
Support for a role of Evi1 as a leukemia initiating 
and promoting oncogene has been obtained through 
mouse bone marrow transduction/transplantation 
models, in which overexpression of Evi1 alone 
caused a myelodysplastic syndrome (MDS) like 
disease, while its co-expression with other 
oncogenes led to AML (Buonamici et al, 2004; Jin 
et al, 2007; Watanabe-Okochi et al, 2008; Watanabe-
Okochi et al, 2013). Even more compellingly, in a 
human gene therapy trial for chronic granulomatous 
disease, activating integrations of the therapeutic 
vector into the MECOM locus led to clonal 
expansion with progression to MDS and, ultimately, 
AML (Stein et al, 2010). Evi1 was proposed to be 
essential for AML leukemia stem cell (LSC) 
function since its experimental down-regulation 
reduced leukemogenicity in several mouse models of 
AML (Goyama et al, 2008; Bindels et al, 2012). Evi1 
expression was also associated with leukemia 
initiating capacity in chronic myeloid leukemia 
(CML) (Sato et al, 2014). A prominent role of EVI1 
in therapy resistance was suggested by a number of 
clinical trials, and illustrated by in vitro data 
demonstrating that its ectopic expression reduced, 
and its knockdown enhanced, cellular 
responsiveness to chemotherapeutic drugs (Bindels 
et al, 2012; Konantz et al, 2012; Yamakawa et al, 
2012; Rommer et al, 2013). 
Beyond its roles in normal and malignant 
hematopoiesis, EVI1 negatively regulated NF-kB 
dependent inflammation (Xu et al, 2012) and 
promoted adipocyte differentiation (Ishibashi et al, 
2012). 
EVI1 exerts its biological functions mainly by acting 
as a transcription factor. and regulates the expression 
of both protein coding and miRNA genes. Reported 
direct EVI1 target genes are MS4A3 (Heller et al, 
2015), PLZF (Takahashi and Licht, 2002), Gata2 
(Yuasa et al; 2005), Pbx1 (Shimabe et al, 2009), Pten 
(Yoshimi et al, 2011), Gpr56 (Saito et al, 2013), 
DeltaNp63 (Nayak et al, 2013), Bcl-xL (Pradhan et 
al, 2011), Calreticulin (Qiu et al, 2008), 
Ppargamma2 (Ishibashi et al, 2012), miR-1-2 
(Gomez-Benito et al, 2010), miR-9 (Senyuk et al, 
2013), miR-124 (Dickstein et al, 2010), and miR-
449A (De Weer et al, 2011). ChIP-seq, combined 
with genome wide gene expression profiling, has 
been employed for large-scale identification of EVI1 
target genes in ovarian cancer and murine myeloid 
cell lines (Bard-Chapeau et al, 2012; Glass et al, 
2013). EVI1 associates with a number of 
transcriptional cofactors like HDAC1 (Vinatzer et al, 
2001), CtBP1 (Palmer et al, 2001), CtBP2 (Turner 
and Crossley, 1998), CBP, P/CAF (Chakraborty et 
al, 2001), the histone methyl transferases SUV39H1 
and G9a (Spensberger et al, 2008a; Goyama et al, 
2010), the ATP dependent helicases BRG1 and 
BRM (Chi et al, 2003), and the member of histone 
deacetylase complex, Mbd3b (Spensberger et al, 
2008b). EVI1 was also shown to interact with DNA 
methyl transferases (Lugthart et al, 2011; Senyuk et 
al, 2011), leading to methylation of CpG islands of 
some of its target genes, among them, CADM1 
(Fisser et al, 2014), miR-9 (Senyuk et al, 2013), and 
miR-124 (Dickstein et al, 2010).  
MECOM (Ecotropic Viral Integration Site 1 (EVI1) and 
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Normal and leukemia-associated EVI1 protein variants. 
 
Furthermore, EVI1 interacted with, and modulated 
the function of, other sequence specific transcription 
factors, e.g. GATA1 (Laricchia-Robbio et al, 2006), 
RUNX1/AML1 (Senyuk et al, 2007), PU.1 
(Laricchia-Robbio et al, 2009), SMAD3 (Kurokawa 
et al, 1998; Izutsu et al, 2001; Alliston et al, 2005), 
FOS (Bard-Chapeau et al, 2012), NFkB (Xu et al, 
2012), and RAR/RXR (Bingemann et al, 2009; 
Steinmetz et al, 2014). 
In addition to its activity as a regulator of 
transcription, EVI1 has been reported to inhibit c-jun 
N-terminal kinase (Kurokawa et al, 2000), and to 
stimulate PI3K/AKT signalling (Liu et al, 2006; 
Yoshimi et al, 2011). 
Homology 
EVI1 orthologs are present in many species. EVI1 
proteins from other mammals share more than 90% 
amino acid sequence identity with the human 
protein, and Xenopus EVI1 is 77% identical to its 
human counterpart. MDS1-EVI1 shares an overall 
homology with the C. elegans Egl 43 protein that 
includes the PR domain at the N-terminus and the 
two zinc-finger domains.  
An MDS1/EVI1 ortholog, hamlet, is also present in 
Drosophila. 
Implicated in 
t(3;3)(q21;q26) or inv(3)(q21q26) 
Note 
3q21q26 syndrome. Chromosomal rearrangements 
located either 5' or 3' of the EVI1 gene can activate 
its transcription in haematopoietic cells. 
t(3;3)(q21;q26) breakpoints are often located 5' of 
EVI1, and inv(3)(q21q26) breakpoints 3' of it. In 
either case, transcription of EVI1 is activated by the 
distal enhancer of the GATA2 gene that is located in 
3q21 (Gröschel et al, 2014; Yamazaki et al, 2014). 
 
Disease 
Acute Myelogenous Leukemia (AML), 
Myelodysplastic Syndrome (MDS), and Chronic 
Myelogenous Leukemia (CML). 
Prognosis 
Patients with EVI1 rearrangements have elevated 
platelet counts, marked hyperplasia with dysplasia of 
megakaryocytes, and a poor prognosis. 
Cytogenetics 
Rearrangements at 3q26 may occur as a sole 
anomaly, but are often associated with monosomy 7 
or deletion of the long arm of chromosome 7, and, 
less frequently, deletion in chromosome 5. 
Oncogenesis 
Inappropriate expression of EVI1 in haematopoietic 
cells alters differentiation into granulocytes, 
erythrocytes and megakaryocytes.  
EVI1 promotes the proliferation of certain cell types, 
but inhibits the growth of others.  
It interferes with growth inhibition by TGF-b and 
with apoptosis elicited by a variety of stimuli.  
In a murine bone marrow 
transduction/transplantation model, experimental 
expression of EVI1 caused a disease resembling 
human myelodysplastic syndrome (Buonamici et al, 
2004), while its coexpression with Hoxa9 and Meis 
1, a mutated RUNX1 gene, or LIP led to overt 
leukemia (Jin et al, 2007; Watanabe-Okochi et al, 
2008; Watanabe-Okochi et al, 2013). 
t(3;12)(q26;p13) 
Disease 
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Abnormal protein 
Overexpression of a fusion protein between the 
amino terminus of ETV6, which does not contain 
any functional domains, and the entire MDS1/EVI1 
protein is driven by the ETV6 promoter. 
t(3;21)(q26;q22) 
Disease 









RUNX1/MDS1/EVI1 is a chimeric transcription 
factor that interferes with RUNX1 functions in a 
dominant negative manner, but shares some 
biological effects with EVI1. 
Various cancers with known fusion 
genes 
Cytogenetics 
Other translocations involving MECOM at 3q26 
have been found:  
t(2;3)(p21;q26) THADA/MECOM in acute myeloid 
leukemia  
t(2;3)(p16;q26) BCL11A/MECOM in acute myeloid 
leukemia  
t(2;3)(q11;q26) MECOM/LMAN2L in ovarian 
carcinoma (Yoshihara et al., 2014)  
t(3;3)(q21;q26) LINC01565/MECOM in acute 
myeloid leukemia (Pekarsky et al., 1997)  
t(3;7)(q26;q21) MECOM/CDK6 in myeloid 
leukemias  
t(3;7)(q26;q34) TRB/MECOM in acute myeloid 
leukemia (M0-AML) (Suzukawa et al., 1999)  
t(3;8)(q26;q24) PVT1/MECOM in acute myeloid 
leukemia and myelodysplastic syndrome  
t(3;15)(q26;p13) MECOM/FRMD5 in lung 
adenocarcinoma (Yoshihara et al., 2014)  
t(3;21)(q26;q21) NRIP1/MECOM in acute myeloid 
leukemia (Haferlach et al., 2012) 
AML without 3q26 rearrangements. 
Disease 
EVI1 may also be overexpressed in AML, MDS, or 
CML in blast crisis in the absence of any 
cytogenetically detectable 3q26 rearrangements. 
Prognosis 
Poor (AML). 
Acute lymphoblastic leukemia 
Note 
Overexpression of EVI1 reported in some cases 
(Konantz et al, 2013; Su et al, 2015) 
Chronic lymphoblastic leukemia 
Prognosis 
Low EVI1 expression levels are associated with 
shorter survival (Vasyutina et al, 2015). 
Fanconi anemia 
Note 
Overexpression of EVI1 (Meyer et al, 2007; Meyer 
et al, 2011) 
Ovarian cancer 
Note 
Overexpression of EVI1 
Prognosis 
Poor (Nanjundan et al, 2007) 
Estrogen receptor negative breast 
cancer 
Note 
Overexpression of EVI1 
Prognosis 
Poor (Patel et al, 2010) 
Infratentorial ependymoma 
Note 
Overexpression of EVI1 
Prognosis 
Poor (Koos et al, 2011) 
Pancreatic cancer 
Note 
Overexpression of EVI1 (Tanaka et al, 2014) 
Colon cancer 
Overexpression of EVI1 (Deng et al, 2013) 
MECOM (Ecotropic Viral Integration Site 1 (EVI1) and 












See figure above.  
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